Fda authorizes phase ii study for natrunix in rheumatoid arthritis patients

Xbiotech believes its drug candidate natrunix could revolutionize arthritis treatment xbiotech believes its drug candidate natrunix could revolutionize arthritis treatment

XBIT Ratings Summary

XBIT Quant Ranking